• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconValeant

Valeant

Page 3 of 12
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
HealthT. Rowe Price Sues Valeant Over Alleged Fraud
By Sy MukherjeeAugust 18, 2016
FinanceHere’s Why Shares of Valeant are Soaring
By Lucinda ShenAugust 17, 2016
Berkshire Hathaway Inc. Annual General Meeting
FinanceHow Valeant Defies the Warren Buffett School of Investing
By Jen WiecznerAugust 11, 2016
Trading At The NYSE As Valeant Shares Halted Ahead of News Announcement
FinanceValeant Executives May Be Facing Criminal Prosecution
By ReutersAugust 10, 2016
Squawk Box - Season 20
FinanceBill Ackman Met Big Investors About Valeant at a Private Brainstorming Dinner
By ReutersAugust 10, 2016
Valeant Pharmaceuticals International Inc. Executives Testify At Senate Hearing On Drug Prices
FinanceValeant’s Troubles Aren’t Driving It To Lower Drug Prices
By Jen WiecznerAugust 9, 2016
HealthValeant’s CEO Says He Is Not Actively Shopping Core Assets
By ReutersAugust 9, 2016
The headquarters of Valeant Pharmaceuticals International, Inc. stands in Bridgewater Township, U.S., on Wednesday Nov. 04, 2015. Photographer: Michael Nagle/Bloomberg
HealthHere’s Why Shares of Valeant Are Jumping
By ReutersAugust 9, 2016
The headquarters of Valeant Pharmaceuticals International, Inc. stands in Bridgewater Township, U.S., on Wednesday Nov. 04, 2015. Photographer: Michael Nagle/Bloomberg
FinanceWidely Loathed Valeant Pharmaceuticals Gets New Top Lawyer and PR Exec
By ReutersAugust 8, 2016
HealthWhistleblower Claims Celgene Colluded With Charities to Drive Profits
By Sy MukherjeeAugust 1, 2016
Trading At The NYSE As Valeant Shares Halted Ahead of News Announcement
HealthThe FDA Sees a Problem with Valeant’s New Glaucoma Eye Drops
By ReutersJuly 22, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
FinanceInvestors Pull $600M After Ackman’s Bad Bets
By Michelle CelarierJuly 19, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
FinanceFormer Valeant CEO Michael Pearson Just Sold About Five Million Shares of the Company
By Lucinda ShenJuly 13, 2016
PETA protesters against the use of meat blocked Re
FinanceValeant’s Second Largest Investor Just Dumped the Rest of Its Stock
By Lucinda ShenJuly 13, 2016
The headquarters of Valeant Pharmaceuticals International, Inc. stands in Bridgewater Township, U.S., on Wednesday Nov. 04, 2015. Photographer: Michael Nagle/Bloomberg
HealthNew Valeant CEO Meets Investors Amid Company Struggles
By ReutersJune 14, 2016
1
  • 1
  • 2
  • 3
  • 4
  • 5
...12
Most Popular
Law
DOGE cancelled a $349,000 grant to replace a museum’s HVAC after ChatGPT flagged it as DEI, court documents showAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Social Security has 6 years left. The fix that sounds cruelest may be the smartestAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Jerome Powell says you're right to blame data centers for making your bills more expensive: 'probably pushing inflation up'An image of a popular article
By Fortune EditorsMarch 19, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.